David Veitch | BiotechTV

top of page

Pareto Securities Healthcare Conference: Basilea is using its financial strength from two marketed products to develop its pipeline and acquire new products - it just received more BARDA funding today

CEO David Veitch walks us through the U.S. launch of Zevtera, and discusses where Cresemba is in its global commercial lifecycle. Plus,...

Company News

Sep 16

Basilea, a profitable anti-infectives company, today landed a contract with BARDA worth up to $268M to develop antifungals and antibiotics

CEO David Veitch describes the news and expands on the success of Basilea's business model.

Company News

Sep 19, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

Pareto Securities Healthcare Conference: Basilea is using its financial strength from two marketed products to develop its pipeline and acquire new products - it just received more BARDA funding today

Basilea, a profitable anti-infectives company, today landed a contract with BARDA worth up to $268M to develop antifungals and antibiotics

Follow BiotechTV

Sponsors

Sponsor Spotlight